Showing results (91-100 of 121) with videos related to

Sort By:
Pageof 13
Journal of Neurochemistry|June 3, 2015
Discovering the mechanisms underlying serotonin (5-HT)2A and 5-HT2C receptor regulation following nicotine withdrawal in ratsMagdalena Zaniewska, Natalia Alenina, Karolina Wydra, et al.
European Journal of Pharmacology|September 13, 2005
The role of 5-HT(2A) receptor antagonism in amphetamine-induced inhibition of A10 dopamine neurons in vitroJohanna E Olijslagers, Benny Perlstein, Taco R Werkman, et al.
European Journal of Pharmacology|August 28, 2014
The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned ratsMaria Papathanou, Peter Jenner, Mahmoud Iravani, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 2, 2008
The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's diseaseNaomi P Visanji, Rob M A de Bie, Tom H Johnston, et al.
Oral Diseases|May 1, 1997
Molecular and phenotypic analysis of Candida dubliniensis: a recently identified species linked with oral candidosis in HIV-infected and AIDS patientsD Coleman, D Sullivan, B Harrington, et al.
European Journal of Pharmacology|December 14, 2004
Quetiapine increases the firing rate of rat substantia nigra and ventral tegmental area dopamine neurons in vitroTaco R Werkman, Johanna E Olijslagers, Benny Perlstein, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|September 2, 2020
Utilization of Visual Acuity Retroilluminated Charts for the Assessment of Afferent Visual System Dysfunction in a Pediatric Neuroimmunology PopulationPeter V Sguigna, Morgan C McCreary, Darrel L Conger, et al.
Neuropharmacology|April 5, 2025
Behavioral and transcriptomic effects of a novel cannabinoid on a rat valproic acid model of autismSally Loomis, Diogo G Silva, Ranjev Savopoulos, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 4, 2010
An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's diseaseC A Jones, L C Johnston, M J Jackson, et al.
Experimental Neurology|June 4, 2015
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in ratH Iderberg, A C McCreary, M A Varney, et al.
Pageof 13